Clinical Utility of Lipoprotein(a) and LPA Genetic Incident Atherosclerotic Cardiovascular Disease

JAMA Cardiology

6, 287

DOI: 10.1001/jamacardio.2020.5398

Citation Report

#	Article	IF	Citations
2	Carotid Atherosclerosis, Ultrasound and Lipoproteins. Biomedicines, 2021, 9, 521.	1.4	11
3	Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy. Current Atherosclerosis Reports, 2021, 23, 46.	2.0	8
4	Utility of Genetically Predicted Lp(a) (Lipoprotein [a]) and ApoB Levels for Cardiovascular Risk Assessment. Circulation Genomic and Precision Medicine, 2021, 14, e003312.	1.6	6
5	Associations of Genetically Predicted Lp(a) (Lipoprotein [a]) Levels With Cardiovascular Traits in Individuals of European and African Ancestry. Circulation Genomic and Precision Medicine, 2021, 14, e003354.	1.6	21
6	Clinical Utility of Lipoprotein(a) for Screening Does Not Determine Clinical Utility of Lipoprotein(a) for the Patient. JAMA Cardiology, 2021, 6, 1096.	3.0	0
7	Protein-coding repeat polymorphisms strongly shape diverse human phenotypes. Science, 2021, 373, 1499-1505.	6.0	96
8	Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies. Vascular Health and Risk Management, 2021, Volume 17, 527-542.	1.0	15
9	Clinical Utility of Lipoprotein(a) for Screening Does Not Determine Clinical Utility of Lipoprotein(a) for the Patientâ€"Reply. JAMA Cardiology, 2021, 6, 1097.	3.0	1
10	Updates on genetics and molecular biology. Current Opinion in Lipidology, 2021, 32, 333-334.	1.2	0
11	Lipoprotein(a): Knowns, unknowns and uncertainties. Pharmacological Research, 2021, 173, 105812.	3.1	39
12	Associations of plasma metal concentrations with the risks of all-cause and cardiovascular disease mortality in Chinese adults. Environment International, 2021, 157, 106808.	4.8	42
13	Ventricular arrhythmia ablation in the presence of mechanical valve utilization and complications of catheter ablation for ventricular arrhythmia in patients with mechanical prosthetic valves. Journal of Cardiovascular Electrophysiology, 2021, 32, 3165-3172.	0.8	2
14	Genetic testing for familial hypercholesterolemiaâ€"past, present, and future. Journal of Lipid Research, 2021, 62, 100139.	2.0	20
15	Polygenic contribution for familial hypercholesterolemia (FH). Current Opinion in Lipidology, 2021, 32, 392-395.	1.2	1
16	Association between lipoprotein (a) and heart failure with reduced ejection fraction development. Journal of Clinical Laboratory Analysis, 2022, 36, e24083.	0.9	6
17	Polygenic risk scores for the diagnosis and management of dyslipidemia. Current Opinion in Endocrinology, Diabetes and Obesity, 2022, Publish Ahead of Print, .	1.2	1
18	Clinical Prediction Models in Epidemiological Studies: Lessons from the Application of QRISK3 to UK Biobank Data. Journal of Data Science, 2022, , 1-13.	0.5	1
19	Genome-Wide Characterization of a Highly Penetrant Form of Hyperlipoprotein(a)emia Associated With Genetically Elevated Cardiovascular Risk. Circulation Genomic and Precision Medicine, 2022, 15, CIRCGEN121003489.	1.6	5

#	Article	IF	Citations
20	Lipoprotein a: An emerging risk identifier and evolving clinical target. , 2022, 2, 1-3.		0
21	Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target. Heart, 2023, 109, 18-25.	1.2	15
22	Lipoprotein(a), Menopausal Hormone Therapy, and Risk of Coronary Heart Disease in Postmenopausal Individuals. JAMA Cardiology, 2022, 7, 565.	3.0	8
23	Polygenic Risk Scores for AtherosclероticÂCardiovascular Disease inÂthe Asia-PacificÂRegion. JACC Asia, 2021, 1, 294-302.	0.5	0
24	Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care. Frontiers in Genetics, 2022, 13, 905941.	1.1	11
25	The effect of LPA Thr3888Pro on lipoprotein(a) and coronary artery disease is modified by the LPA KIV-2 variant 4925G>A. Atherosclerosis, 2022, 349, 151-159.	0.4	6
26	Strengthening Causal Inference in Exposomics Research: Application of Genetic Data and Methods. Environmental Health Perspectives, 2022, 130, 55001.	2.8	5
27	Lipoprotein(a) beyond the kringle IV repeat polymorphism: The complexity of genetic variation in the LPA gene. Atherosclerosis, 2022, 349, 17-35.	0.4	61
28	Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill?. Atherosclerosis, 2022, 349, 123-135.	0.4	47
29	Mendelian Randomization: Principles and its usage in Lp(a) research. Atherosclerosis, 2022, 349, 36-41.	0.4	16
30	Heart to Heart Nurses Podcast Series. Journal of Cardiovascular Nursing, 2022, 37, 403-404.	0.6	0
32	Lipoprotein(a): Insights for the Practicing Clinician. Journal of Clinical Medicine, 2022, 11, 3673.	1.0	2
34	Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation, 2022, 146, .	1.6	80
35	Lipid Profile, Lp(a) Levels, and HDL Quality in Adolescents with Down Syndrome. Journal of Clinical Medicine, 2022, 11, 4356.	1.0	1
36	Differential associations of lipoprotein(a) level with cerebral large artery and small vessel diseases. Stroke and Vascular Neurology, 2022, 7, 534-540.	1.5	4
37	Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes. Journal of the American College of Cardiology, 2022, 80, 1287-1298.	1.2	45
38	Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal, 2022, 43, 3925-3946.	1.0	290
39	The kringle IV type 2 domain variant 4925G>A causes the elusive association signal of the LPA pentanucleotide repeat. Journal of Lipid Research, 2022, 63, 100306.	2.0	3

#	Article	IF	Citations
40	Lipoprotein(a) and residual vascular risk in statin-treated patients with first acute ischemic stroke: A prospective cohort study. Frontiers in Neurology, 0, 13, .	1.1	3
41	Relationship between serum homocysteine, fibrinogen, lipoprotein-a level, and peripheral arterial disease: a doseâ€“response meta-analysis. European Journal of Medical Research, 2022, 27, .	0.9	3
42	Use of Lipoprotein(a) to improve diagnosis and management in clinical familial hypercholesterolemia. Atherosclerosis, 2023, 365, 27-33.	0.4	9
43	Pediatric Population with Down Syndrome: Obesity and the Risk of Cardiovascular Disease and Their Assessment Using Omics Techniquesâ€”Review. Biomedicines, 2022, 10, 3219.	1.4	1
44	Comprehensive variant discovery in the era of complete human reference genomes. Nature Methods, 2023, 20, 17-19.	9.0	1
45	Improving Cardiovascular Risk Assessment to Optimize Therapy. World Journal of Cardiovascular Diseases, 2023, 13, 7-20.	0.0	1
47	Measurement of Lipoprotein(a) in the Clinical Laboratory. Contemporary Cardiology, 2023, , 281-295.	0.0	0
48	Genetic and clinical factors underlying a self-reported family history of heart disease. European Journal of Preventive Cardiology, 2023, 30, 1571-1579.	0.8	3